Zai Lab will showcase updated results from its Phase 1a/1b trial of ZL-1310, a potentially best-in-class DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer at the 2025 ASCO Annual Meeting.
ZL-1310, a DLL3-targeting antibody-drug conjugate, demonstrated a 74% objective response rate in previously treated extensive-stage small cell lung cancer (ES-SCLC) patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.